Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.
Michael Barish, PhD
Advertisement
Articles by Michael Barish, PhD
Results showed no “deleterious reactions” with chlorotoxin-directed cellular therapy in a small cohort of patients with recurrent glioblastoma.
A novel CAR T-cell therapy may bind with more avidity, rather than affinity, to glioblastoma cells, said Michael Barish, PhD.
Advertisement
Latest Updated Articles
Chlorotoxin-Directed Cell Therapy May Have Useful Mechanism in GlioblastomaPublished: November 8th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Interpreting Overall Survival and Subgroup Outcomes in MATTERHORN: Where DFLOT Shows Strength and Where Questions Remain
2
What’s New in Hematology/Oncology? Discussing the 2025 ASH Annual Meeting
3
Bioimpedance Spectroscopy is Allowing for Lymphedema Reduction in Breast Cancer
4
Nab-Sirolimus Regimens Show Promise in HR+/HER2-Negative Breast Cancer
5